PNC Executive to Speak at UBS Financial Services Conference

The PNC Financial Services Group, Inc. (NYSE: PNC) announced today that Executive Vice President and Chief Financial Officer Robert Q. Reilly will discuss business performance and strategy at 11:20 a.m. (ET), Tuesday, Feb. 11, at the UBS Financial Services Conference in Miami. The following will be accessible at www.pnc.com/investorevents: a link to the live webcast; […]

HOPE Therapeutics™, Inc. and NRx Pharmaceuticals, Inc. (NASDAQ:NRXP) Execute Agreement for $27 Million Funding Transaction for HOPE Clinic Acquisition

— $25 million investment in HOPE to consist of Series A (non-dilutive to NRx shareholders) convertible into 1/3 of fully diluted HOPE equity, with a 15% current preferred dividend (non-callable for 2 years) for planned HOPE clinic acquisitions — Initial funding of $2.0 million for purchase of NRx common stock anticipated to close on or

Vivid Seats and Hopper Release 2025 Big Game Guide

(NASDAQ:SEAT),(NASDAQ:SEATW), Record-Breaking Rematch is Hottest Caesars Superdome Ticket in 17 years Airfares to New Orleans surge for Big Game Weekend CHICAGO, Jan. 28, 2025 (GLOBE NEWSWIRE) — Vivid Seats Inc. (NASDAQ: SEAT), a leading marketplace that utilizes its technology platform to connect millions of buyers with thousands of ticket sellers across hundreds of thousands of

FOXO TECHNOLOGIES, INC., PROVIDES UPDATE ON RECENT ACOMPLISHMENTS AND BUSINESS STRATEGY

(NYSE:FOXO), MINNEAPOLIS, MN, Jan. 28, 2025 (GLOBE NEWSWIRE) — FOXO Technologies Inc. (NYSE American: FOXO) (the “Company”), provides a brief shareholder letter from Seamus Lagan, recently appointed CEO of FOXO on what has been achieved in recent months and what is planned for 2025 and beyond. Dear Fellow Shareholders, Our recent shareholders meeting on January

Vermilion Energy Inc. Announces Filing of Westbrick Financial Information and Increase to Term Loan Facility

Vermilion Energy Inc. (“Vermilion” or the “Company”) (TSX: VET) (NYSE: VET) has filed certain financial information relating to its proposed acquisition of Westbrick Energy Ltd. on its profile on SEDAR+ (www.sedarplus.ca). In addition, the Company has received commitments and consent from lenders to increase the previously announced fully underwritten term loan maturing May 2028 from

Businesses Pay More For Online Customers, But See 6.1% Drop in Conversions as User Frustration Persists

Contentsquare's 2025 Digital Experience Benchmarks Report highlights urgent need to optimize experiences as digital landscape transforms, AI dominates, and consumers demand excellence As companies navigate a highly competitive landscape defined by rising customer expectations and the rapid evolution of AI-powered technologies, new data from Contentsquare's 2025 Digital Experience Benchmarksreleased today suggests that turning traffic into

BELA UNVEILS FIRST BRAND REFRESH IN 28 YEARS, INTRODUCING A NEW LOOK AND DIRECT-TO-CONSUMER EXPERIENCE

Revamped Website and Fresh Branding Signal Exciting New Chapter for BELA's Hand-Packed, Sustainably Sourced Tinned Seafood TodayBELA, a veteran and family-owned tinned fish company known for its commitment to quality and sustainability, unveiled a refreshed brand identity for the first time in 28 years. Along with a bold new look, BELA is introducing a revamped

NRx Pharmaceuticals, Inc. (NASDAQ:NRXP) Advances Relationship with Anson Funds with $8.9 Million Financing, Including Above the Market Equity and Senior Secured Debt

— This financing is expected to support filing of New Drug Applications forNRX-100 (ketamine) and NRX-101, and to support launch of HOPE Therapeutics — Investment consists of $3.5 million in above the market equity and $5.4 million in Senior Secured Notes; expected to fund current operations into 2026 NRx Pharmaceuticals, Inc. (NASDAQ: NRXP) (“NRx”, “NRx

Dagger Named to Ad Age Best Places to Work List for 2025

Agency Wins 4th Major Accolade in Just 5 Years With the Publication Dagger has been named one of the Ad Age Best Places to Work2025, an annual ranking of companies that lead the pack in factors ranging from pay and benefits to corporate culture and leadership. Earning this prestigious award for the second time (2021

Instylla Announces FDA Clearance of Tembo™ Embolic System

Instylla, Inc., a privately held clinical-stage company developing solutions for peripheral vascular embolotherapy, has announced the FDA 510(k) clearance of the Tembo™Embolic System. The Tembo Embolic System is a bioresorbable1 embolization agent comprised of irregularly shaped, dry gelatin particles of a size range from 85-255µm1. These particles are designed for theembolization of hypervascular tumors and

Scroll to Top